Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of TAN-118 in adults with moderate to severe active ulcerative colitis
CTR20261164Phase 2Active
- Sponsor
- Zedman Pharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAN-118 in autoimmune colitis, inflammatory bowel disease (IBD), sponsored by Zedman Pharma. Started Apr 2026; status: active.
02
Drugs
TAN-118
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on CTR20261164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261164.